Zhejiang Anglikang Pharmaceutical Co Ltd Class A Total Assets
Zhejiang Anglikang Pharmaceutical Co Ltd Class A total assets. Based on the latest financial reports, Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) holds total assets worth CN¥2.98 Billion CNY (≈ $435.47 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 002940 company net worth for the company's overall valuation and market capitalisation.
Total Assets of Zhejiang Anglikang Pharmaceutical Co Ltd Class A (2014–2025)
Total assets of Zhejiang Anglikang Pharmaceutical Co Ltd Class A from 2014 to 2025. This chart illustrates how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's total assets have evolved over time, based on quarterly financial data. See 002940 live share price for real-time trading data and today's change.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A - Asset Composition Analysis
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Total Assets Breakdown (December 2025)
Zhejiang Anglikang Pharmaceutical Co Ltd Class A total assets breakdown as of December 2025. Zhejiang Anglikang Pharmaceutical Co Ltd Class A's total assets of CN¥2.98 Billion consist of 50.4% current assets and 49.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 23.3% |
| Accounts Receivable | CN¥176.03 Million | 6.0% |
| Inventory | CN¥447.47 Million | 15.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥173.68 Million | 5.9% |
| Goodwill | CN¥312.94 Million | 10.6% |
Asset Composition Trend (2014–2025)
This chart illustrates how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Zhejiang Anglikang Pharmaceutical Co Ltd short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Anglikang Pharmaceutical Co Ltd Class A's current assets represent 50.4% of total assets in 2025, a decrease from 54.9% in 2014.
- Cash Position: Cash and equivalents constituted 23.3% of total assets in 2025, up from 5.5% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 6.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 15.2% of total assets.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Competitors by Total Assets
Key competitors of Zhejiang Anglikang Pharmaceutical Co Ltd Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.86 Billion |
|
H Lundbeck A/S
CO:HLUN-B
|
Denmark | Dkr54.01 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Viyash Scientific Limited
NSE:SEQUENT
|
India | Rs17.26 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
Zhejiang Anglikang Pharmaceutical Co Ltd Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.99 | 1.77 | 2.67 |
| Quick Ratio | 1.32 | 1.13 | 2.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥764.26 Million | CN¥670.57 Million | CN¥771.96 Million |
Zhejiang Anglikang Pharmaceutical Co Ltd Class A - Advanced Valuation Insights
This section examines the relationship between Zhejiang Anglikang Pharmaceutical Co Ltd Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.84 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | -0.8% |
| Total Assets | CN¥2.95 Billion |
| Market Capitalization | $749.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Anglikang Pharmaceutical Co Ltd Class A's assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Zhejiang Anglikang Pharmaceutical Co Ltd Class A's assets decreased by 0.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Zhejiang Anglikang Pharmaceutical Co Ltd Class A (2014–2025)
The table below shows the annual total assets of Zhejiang Anglikang Pharmaceutical Co Ltd Class A from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.95 Billion ≈ $431.80 Million |
-0.80% |
| 2024-12-31 | CN¥2.97 Billion ≈ $435.27 Million |
-1.51% |
| 2023-12-31 | CN¥3.02 Billion ≈ $441.92 Million |
+16.33% |
| 2022-12-31 | CN¥2.60 Billion ≈ $379.89 Million |
+24.60% |
| 2021-12-31 | CN¥2.08 Billion ≈ $304.89 Million |
+7.36% |
| 2020-12-31 | CN¥1.94 Billion ≈ $283.99 Million |
+40.13% |
| 2019-12-31 | CN¥1.38 Billion ≈ $202.67 Million |
-5.80% |
| 2018-12-31 | CN¥1.47 Billion ≈ $215.14 Million |
+62.13% |
| 2017-12-31 | CN¥906.78 Million ≈ $132.69 Million |
+24.56% |
| 2016-12-31 | CN¥727.99 Million ≈ $106.53 Million |
-8.98% |
| 2015-12-31 | CN¥799.83 Million ≈ $117.04 Million |
+9.35% |
| 2014-12-31 | CN¥731.44 Million ≈ $107.03 Million |
-- |
About Zhejiang Anglikang Pharmaceutical Co Ltd Class A
Zhejiang AngLiKang Pharmaceutical CO.,LTD. engages in the research, development, production, and sale of pharmaceuticals in China and internationally. The company offers chemical raw materials for pharmaceuticals comprising oral cephalosporin antibiotic raw materials, including cephalexin, cefadroxil, cefaclor, and cefadroxil; alpha-keto acid raw materials; inhaled anesthetic raw materials, such … Read more